Protagenic Therapeutics

Protagenic Therapeutics is a public, clinical-stage biotechnology company developing a novel class of therapeutics based on the Teneurin C-terminal Associated Peptide (TCAP) to regulate the stress response system. Founded in 2015, the company's mission is to address the root cause of stress-related disorders like depression, anxiety, PTSD, and addiction, where current treatments are often inadequate. Its strategy involves building a proprietary TCAP platform to efficiently develop multiple drug candidates for a broad spectrum of CNS indications. The lead candidate, PT00114, is advancing into clinical trials, representing a potentially transformative approach to neuronal health.

Proprietary Teneurin C-terminal Associated Peptide (TCAP) platform, leveraging an evolutionarily conserved neuropeptide that acts as the body's intrinsic regulator of the stress response system to develop first-in-class therapeutics for CNS disorders.

Competes in crowded CNS markets but claims a unique niche targeting the endogenous stress regulator TCAP. Faces competition from standard antidepressants, novel rapid-acting therapies, and other neuropeptide platforms, but first-in-class status provides initial differentiation.